메뉴 건너뛰기




Volumn 5, Issue 2, 2007, Pages 323-330

Vasopressin antagonists in the management of heart failure

Author keywords

Bodyweight; Cardiac failure; Diuretics; Hyponatremia; Tolvaptan; Vasopressin antagonist

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; LIXIVAPTAN; LOOP DIURETIC AGENT; MILRINONE; NESIRITIDE; PLACEBO; SODIUM; THIAZIDE DIURETIC AGENT; TOLVAPTAN; UNCLASSIFIED DRUG; VASODILATOR AGENT; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR ANTAGONIST;

EID: 33947681647     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.2.323     Document Type: Review
Times cited : (4)

References (43)
  • 2
    • 14844291419 scopus 로고    scopus 로고
    • Characteristics and outcomes of patients hospitalised for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated HEart failure national REgistry (ADHERE)
    • for the ADHERE Scientific Advisory Committee and Investigators
    • Adams KF, Fonarow GC, Emerman CL et al; for the ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalised for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated HEart failure national REgistry (ADHERE). Am. Heart J. 149, 209-213 (2005).
    • (2005) Am. Heart J. , vol.149 , pp. 209-213
    • Adams, K.F.1    Fonarow, G.C.2    Emerman, C.L.3
  • 3
    • 0036915820 scopus 로고    scopus 로고
    • Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study
    • Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J. 144, 1102-1108 (2002).
    • (2002) Am. Heart J. , vol.144 , pp. 1102-1108
    • Burger, A.J.1    Horton, D.P.2    LeJemtel, T.3
  • 4
    • 29344447073 scopus 로고    scopus 로고
    • Role of diminished renal function in cardiovascular mortality
    • Schrier RW. Role of diminished renal function in cardiovascular mortality. J. Am. Coll. Cardiol. 47, 1-8 (2006).
    • (2006) J. Am. Coll. Cardiol. , vol.47 , pp. 1-8
    • Schrier, R.W.1
  • 5
    • 10744231948 scopus 로고    scopus 로고
    • Relationship between heart failure treatment and development of worsening renal function among hospitalized patients
    • Butler J, Forman D, Abram W et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am. Heart J. 147, 331-338 (2004).
    • (2004) Am. Heart J. , vol.147 , pp. 331-338
    • Butler, J.1    Forman, D.2    Abram, W.3
  • 6
    • 27644543953 scopus 로고    scopus 로고
    • Therapeutics in congestive heart failure: From hemodynamics to neurohormones
    • In: Singh PK, Dixon I, Kirschenbaum LA, Dhalla NS (Eds). Kluwer Academic Publishers, MA, USA
    • Goldsmith SR. Therapeutics in congestive heart failure: from hemodynamics to neurohormones. In: Cardiac Remodeling and Failure. Singh PK, Dixon I, Kirschenbaum LA, Dhalla NS (Eds). Kluwer Academic Publishers, MA, USA 17-34 (2003).
    • (2003) Cardiac Remodeling and Failure , pp. 17-34
    • Goldsmith, S.R.1
  • 7
    • 2742581427 scopus 로고    scopus 로고
    • Renal sodium excretion, edematous disorders, and diuretic use
    • In: Schrier RW (Ed.). Lippincott Williams and Wilkins, PA, USA
    • Schrier RW, Gurevich A, Abraham W. Renal sodium excretion, edematous disorders, and diuretic use. In: Renal and Electrolyte Disorders. (6th Edition). Schrier RW (Ed.). Lippincott Williams and Wilkins, PA, USA 64-114 (2002).
    • (2002) Renal and Electrolyte Disorders. (6th Edition) , pp. 64-114
    • Schrier, R.W.1    Gurevich, A.2    Abraham, W.3
  • 8
    • 33644871184 scopus 로고    scopus 로고
    • Hyponatremia in patients with heart failure
    • De Luca L, Klein L, Udelson JE et al. Hyponatremia in patients with heart failure. Am. J. Cardiol. 96(12A), 19L-23L (2005).
    • (2005) Am. J. Cardiol. , vol.96 , Issue.12 A
    • De Luca, L.1    Klein, L.2    Udelson, J.E.3
  • 9
    • 18844423537 scopus 로고    scopus 로고
    • Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study
    • OPTIME-CHF Investigators
    • Klein L, O'Connor CM, Leimberger JD et al, OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111(l9), 2454-2460 (2005).
    • (2005) Circulation , vol.111 , Issue.19 , pp. 2454-2460
    • Klein, L.1    O'Connor, C.M.2    Leimberger, J.D.3
  • 10
    • 0019861237 scopus 로고
    • Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure
    • Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N. Engl. J. Med. 305, 263-266 (1981).
    • (1981) N. Engl. J. Med. , vol.305 , pp. 263-266
    • Szatalowicz, V.L.1    Arnold, P.E.2    Chaimovitz, C.3    Bichet, D.4    Schrier, R.W.5
  • 12
    • 0014279821 scopus 로고
    • Plasma ADH level in patients with chronic congestive heart failure
    • Yamane Y. Plasma ADH level in patients with chronic congestive heart failure. Japan Circ. J. 32, 745-759 (1968).
    • (1968) Japan Circ. J. , vol.32 , pp. 745-759
    • Yamane, Y.1
  • 14
    • 0031703592 scopus 로고    scopus 로고
    • Recent advances in the understanding of water metabolism in heart failure
    • Schrier RW, Martin PY. Recent advances in the understanding of water metabolism in heart failure. Adv. Exp. Med. Biol. 449, 415-426 (1998).
    • (1998) Adv. Exp. Med. Biol. , vol.449 , pp. 415-426
    • Schrier, R.W.1    Martin, P.Y.2
  • 15
    • 0010659406 scopus 로고
    • Baroreflex control of vasopressin secretion in normal humans
    • In: Cowley AW, Liard J-F, Ausiello DA (Eds). Raven Press, NY, USA
    • Goldsmith SR. Baroreflex control of vasopressin secretion in normal humans. In: Vasopressin: Cellular and Integrative Functions. Cowley AW, Liard J-F, Ausiello DA (Eds). Raven Press, NY, USA 389-397 (1988).
    • (1988) Vasopressin: Cellular and Integrative Functions , pp. 389-397
    • Goldsmith, S.R.1
  • 16
    • 33947633785 scopus 로고
    • Central catecholamine pathways to vasopressin neurons
    • In: Schrier RW (Ed.). Raven Press NY, USA
    • Sladek JR Jr. Central catecholamine pathways to vasopressin neurons. In: Vasopressin. Schrier RW (Ed.). Raven Press NY, USA 343-352 (1985).
    • (1985) Vasopressin , pp. 343-352
    • Sladek Jr., J.R.1
  • 17
    • 0033373438 scopus 로고    scopus 로고
    • Vasopressin: A therapeutic target in congestive heart failure?
    • Goldsmith SR. Vasopressin: a therapeutic target in congestive heart failure? J. Card. Fail. 5, 347-356 (1999).
    • (1999) J. Card. Fail. , vol.5 , pp. 347-356
    • Goldsmith, S.R.1
  • 18
    • 0023795642 scopus 로고
    • Mechanisms of action of vasopressin and vasopressin antagonists
    • Jard S. Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int. Suppl. 26, S38-S42 (1988).
    • (1988) Kidney Int. Suppl. , vol.26
    • Jard, S.1
  • 19
    • 0025820750 scopus 로고
    • +] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors
    • +] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ. Res. 69, 239-245 (1991).
    • (1991) Circ. Res. , vol.69 , pp. 239-245
    • Xu, Y.J.1    Gopalakrishnan, V.2
  • 20
    • 0034629529 scopus 로고    scopus 로고
    • Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor
    • Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor. Eur. J. Pharmacol. 391, 39-48 (2000).
    • (2000) Eur. J. Pharmacol. , vol.391 , pp. 39-48
    • Nakamura, Y.1    Haneda, T.2    Osaki, J.3    Miyata, S.4    Kikuchi, K.5
  • 21
    • 0022461967 scopus 로고
    • Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit
    • Arnolda L, McGrath BP, Cocks M, Johnston CI. Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit. J. Clin. Invest. 78, 674-679 (1986).
    • (1986) J. Clin. Invest. , vol.78 , pp. 674-679
    • Arnolda, L.1    McGrath, B.P.2    Cocks, M.3    Johnston, C.I.4
  • 23
    • 0028558373 scopus 로고
    • Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
    • Naitoh M, Suzuki H, Murakami M et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol, 267, H2245-H2254 (1994).
    • (1994) Am. J. Physiol. , vol.267
    • Naitoh, M.1    Suzuki, H.2    Murakami, M.3
  • 24
    • 0027296317 scopus 로고
    • Biochemical and pharmacologic properties of SR 49059, a new potent nonpeptide antagonist of rat and human vasopression V1 receptors
    • Serradeil-Ledel C, Wagon J, Garcia G et al. Biochemical and pharmacologic properties of SR 49059, a new potent nonpeptide antagonist of rat and human vasopression V1 receptors. J. Clin. Invest. 92, 224-231 (1993).
    • (1993) J. Clin. Invest. , vol.92 , pp. 224-231
    • Serradeil-Ledel, C.1    Wagon, J.2    Garcia, G.3
  • 25
    • 0035856509 scopus 로고    scopus 로고
    • Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure
    • Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104, 2417-2423 (2001).
    • (2001) Circulation , vol.104 , pp. 2417-2423
    • Udelson, J.E.1    Smith, W.B.2    Hendrix, G.H.3
  • 26
    • 11144355788 scopus 로고    scopus 로고
    • Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial (ACTIV)
    • for the Acute and Chronic Therapeutic Impact of a Vasopressin antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators
    • Gheorghiade M, Gattis WA, O'Connor CM et al, for the Acute and Chronic Therapeutic Impact of a Vasopressin antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV). JAMA 291, 1963-1971 (2004).
    • (2004) JAMA , vol.291 , pp. 1963-1971
    • Gheorghiade, M.1    Gattis, W.A.2    O'Connor, C.M.3
  • 27
    • 0037904417 scopus 로고    scopus 로고
    • Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure
    • Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation 107, 2690-2696 (2003).
    • (2003) Circulation , vol.107 , pp. 2690-2696
    • Gheorghiade, M.1    Niazi, I.2    Ouyang, J.3
  • 28
    • 0022653171 scopus 로고
    • Hospital associated hyponatremia
    • Anderson RJ. Hospital associated hyponatremia. Kidney Int. 29, 1237-1247 (1986).
    • (1986) Kidney Int. , vol.29 , pp. 1237-1247
    • Anderson, R.J.1
  • 29
    • 0029816077 scopus 로고    scopus 로고
    • Correlates of major complications or death in patients admitted to the hospital with congestive heart failure
    • Chin MW, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch. Intern. Med. 156, 1814-1820 (1996).
    • (1996) Arch. Intern. Med. , vol.156 , pp. 1814-1820
    • Chin, M.W.1    Goldman, L.2
  • 30
    • 0022637771 scopus 로고
    • Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure
    • Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation 73, 257-267 (1986).
    • (1986) Circulation , vol.73 , pp. 257-267
    • Lee, W.H.1    Packer, M.2
  • 31
    • 33751005260 scopus 로고    scopus 로고
    • SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia
    • Schrier RW, Gross P, Gheorghiade M et al; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355(20), 2099-2112 (2006).
    • (2006) N. Engl. J. Med. , vol.355 , Issue.20 , pp. 2099-2112
    • Schrier, R.W.1    Gross, P.2    Gheorghiade, M.3
  • 32
    • 0037223321 scopus 로고    scopus 로고
    • A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial
    • Wong F, Blei AT, Blendis LM et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37, 182-191 (2003).
    • (2003) Hepatology , vol.37 , pp. 182-191
    • Wong, F.1    Blei, A.T.2    Blendis, L.M.3
  • 33
    • 33947646654 scopus 로고    scopus 로고
    • Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: Insights from the Acute and Chronic Therapeutic Impact of a Vasopressin antagonist in Chronic Heart Failure (ACTIV in CHF) trial
    • (Abtstract)
    • Gheorghiade M, Adams K, O'Connor C et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin antagonist in Chronic Heart Failure (ACTIV in CHF) trial. J. Am. Coll. Cardiol. 145A (2005) (Abtstract).
    • (2005) J. Am. Coll. Cardiol. , vol.145 A
    • Gheorghiade, M.1    Adams, K.2    O'Connor, C.3
  • 34
    • 20944445209 scopus 로고    scopus 로고
    • Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)
    • Gheorghiade M, Orlandi C, Burnett JC et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J. Card. Fail. 11, 260-269 (2005).
    • (2005) J. Card. Fail. , vol.11 , pp. 260-269
    • Gheorghiade, M.1    Orlandi, C.2    Burnett, J.C.3
  • 35
    • 0037221858 scopus 로고    scopus 로고
    • Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial
    • Russell SD, Selaru P, Pyne DA et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial. Am. Heart J. 145, 179-186 (2003).
    • (2003) Am. Heart J. , vol.145 , pp. 179-186
    • Russell, S.D.1    Selaru, P.2    Pyne, D.A.3
  • 36
    • 2742581427 scopus 로고    scopus 로고
    • Renal sodium excretion, edematous disorders, and diuretic use
    • In: Schrier RW (Ed.). Lippincott Williams and Wilkins, PA, USA
    • Schrier RW, Gurevich AK, Abraham WT. Renal sodium excretion, edematous disorders, and diuretic use. In: Renal and Electrolyte Disorders (6th Edition). Schrier RW (Ed.). Lippincott Williams and Wilkins, PA, USA 72-73 (2003).
    • (2003) Renal and Electrolyte Disorders (6th Edition) , pp. 72-73
    • Schrier, R.W.1    Gurevich, A.K.2    Abraham, W.T.3
  • 37
    • 0033955058 scopus 로고    scopus 로고
    • Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure
    • Gottlieb S, Skettino SL, Wolff A et al. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J. Am. Coll. Cardiol. 35, 56-59 (2000).
    • (2000) J. Am. Coll. Cardiol. , vol.35 , pp. 56-59
    • Gottlieb, S.1    Skettino, S.L.2    Wolff, A.3
  • 38
    • 33947682516 scopus 로고    scopus 로고
    • Chronic diuretics, renal dysfunction raise mortality risk in decompensated heart failure
    • Presented at: New Orleans, LA, USA, 7-10 March
    • Aronson D. Chronic diuretics, renal dysfunction raise mortality risk in decompensated heart failure. Presented at: American College of Cardiology 2004 Scientific Sessions New Orleans, LA, USA, 7-10 March, 2004.
    • (2004) American College of Cardiology 2004 Scientific Sessions
    • Aronson, D.1
  • 39
    • 9144262490 scopus 로고    scopus 로고
    • Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure
    • Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol, 43, 61-67 (2004).
    • (2004) J. Am. Coll. Cardiol. , vol.43 , pp. 61-67
    • Forman, D.E.1    Butler, J.2    Wang, Y.3
  • 40
    • 0032799699 scopus 로고    scopus 로고
    • Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure
    • Weinfeld MS, Chertow GM, Stevenson LW, Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am. Heart J. 138, 285-290 (1999).
    • (1999) Am. Heart J. , vol.138 , pp. 285-290
    • Weinfeld, M.S.1    Chertow, G.M.2    Stevenson, L.W.3
  • 41
    • 0034636845 scopus 로고    scopus 로고
    • Renal function, neurohormonal activation, and survival in patients with chronic heart failure
    • Hillege HL, Girbes, AR, de Kam P et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102, 203-210 (2000).
    • (2000) Circulation , vol.102 , pp. 203-210
    • Hillege, H.L.1    Girbes, A.R.2    de Kam, P.3
  • 42
    • 33947656199 scopus 로고    scopus 로고
    • Chronic diuretics, renal dysfunction raise mortality risk in decompensated heart failure
    • Presented at: New Orleans, LA, USA, 7-10 March
    • Costanzo MR. Chronic diuretics, renal dysfunction raise mortality risk in decompensated heart failure. Presented at: American College of Cardiology 2004 Scientific Sessions New Orleans, LA, USA, 7-10 March, 2004.
    • (2004) American College of Cardiology 2004 Scientific Sessions
    • Costanzo, M.R.1
  • 43
    • 0033592418 scopus 로고    scopus 로고
    • Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction
    • Cooper HA, Dries DL, Davis CE et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100, 1311-1315 (1999).
    • (1999) Circulation , vol.100 , pp. 1311-1315
    • Cooper, H.A.1    Dries, D.L.2    Davis, C.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.